Eddy Lee
About Eddy Lee
Eddy Lee serves as the Senior Vice President of Technical Operations at Mirati Therapeutics, where he has worked since 2023. He has over three decades of experience in the pharmaceutical industry, holding key positions at various companies, including Turning Point Therapeutics and Genzyme.
Current Role at Mirati Therapeutics
Eddy Lee serves as the Senior Vice President of Technical Operations at Mirati Therapeutics. He has held this position since 2023 and is based in San Diego, California. In this role, he is responsible for overseeing technical operations, including the management of manufacturing processes and ensuring compliance with industry standards.
Previous Experience at Turning Point Therapeutics
Prior to his current role, Eddy Lee worked at Turning Point Therapeutics as Senior Vice President of CMC from 2022 to 2023. During his tenure, he successfully led the manufacturing and NDA submission for Repotrectinib, contributing to the company's operational goals in San Diego, California.
Background in Chemical Process Development
Eddy Lee has a long history in chemical process development, having worked at Genzyme as Vice President and Head of Chemical Process Development for 22 years, from 1990 to 2012. His responsibilities included developing the manufacturing process for Cerdelga™ oral Eliglustat Tartrate, showcasing his expertise in the pharmaceutical manufacturing sector.
Educational Qualifications in Organic Chemistry
Eddy Lee holds a Doctor of Philosophy (PhD) in Organic Chemistry from the University of Warwick, where he studied from 1985 to 1988. He also completed a Post-doctoral study in Organic Chemistry at the University of Bern from 1988 to 1989. Additionally, he earned a Bachelor of Science (BS) in Chemistry from the University of Warwick from 1982 to 1985.
Achievements in Manufacturing and Development
Throughout his career, Eddy Lee has played a significant role in various pharmaceutical projects. He managed the manufacturing processes for Lorecivivint and SMO8502 at Biosplice Therapeutics and was instrumental in the development and launch of Xipere at Clearside Biomedical. He has also developed a global network of manufacturers and suppliers, enhancing operational capabilities in the industry.